Interview with Patrick Aghanian, General Manager, Sanofi Russia
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Address: 125009, Россия, Москва ул. Тверская, дом 22 Бизнес центр ‘Саммит’ 8 этаж,Russia
Tel: +7 495 721 14 00
Web: http://www.sanofi.ru/l/ru/ru/index.jsp
Sanofi is a diversified global healthcare company focused on patients’ needs. Sanofi is a leader in emerging markets and one of the leading pharmaceutical companies in Europe, it is the world leader in human vaccines and animal health. The Group is present in 100 countries on five continents with almost 100,000 employees. Headquarter of the company is located in Paris.
Sanofi Russia has been present in Russia since 1970. Sanofi offers a large portfolio of original medicines, generics and OTC drugs in key therapeutic areas: diabetes, oncology, cardiovascular diseases, CNS diseases, internal medicine and thrombosis.
Vaccine production is one of Sanofi priorities. Sanofi Pasteur, the vaccine division of the Group, is the world leader in human vaccine production and development. Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. In 2008 it started inactivated polio vaccine production in co-operation with M.P. Chumakov Poliomyelitis and Viral Encephalitis Institute of the Russian Academy of Medical Science for the National Vaccination Calendar.
In March 2009 Zentiva, the leader in the generics segment in CEE markets, became a member of the Group.
In 2010 Sanofi acquired a modern insulin factory located in the Orel region. Sanofi-Aventis Vostok is company’s manufacturing facility for production of human insulin and insulin analogs in hi-tech pens in Russia. At this moment installed production lines can provide from 15 to 30 m. units of insulin dosed forms every year. It is planned to reach full capacity and full insulin production cycle (excuding production of active pharmaceutical ingredient, API) in early 2012.
Improvement of treatment of Russian patients is one of the key objectives of Sanofi group. The company supports large-scale national educational programs in all therapeutic areas. Sanofi launched over 190 specialized epilepsy centers (epicenters) fully equipped and operating as training centers for doctors, over 50 atherothrombosis schools (atheroschools) for doctors under support of the National Atherothrombosis Society. Starting from August 2009, the company has been carrying out all-Russia medico-social program “Help for Heart” to support patients who had instable angina (IA) or myocardial infarction (MI).
Starting from autumn 2009, Sanofi has been implementing all-Russia educational program for diabetes patients “Every day is yours” together with the leading Russian endocrinologists.
Starting from 2011 Sanofi Russia implements social program “Chance to life” aimed at improving the quality of life of women at early stages of breast cancer (BC). In the framework of this program Sanofi Russia will support 2000 patients with early stages of breast cancer supplying high quality medicine for up-to-date treatment in 2011. Starting from August 2011 Sanofi Russia together with the Health department of the Orel region and regional oncology center will start implementing breast cancer patients support program in the Orel region. In 2011 the program will cover 230 patients with BC who should receive chemotherapy with highly efficient modern drugs.Charitable activity of Sanofi Russia is consolidated by the program “Give a Smile”. Its aim is to help children from orphanages, to give orphans joy, warmth and smiles through attention and communication. Employees take an active part in the program. The program grew from single charity actions and in 2010 covered all Russian regions.
Sanofi offers a large portfolio of original medicines, generics and OTC drugs in key therapeutic areas: diabetes, oncology, cardiovascular diseases, CNS diseases, internal medicine and thrombosis.
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here